TPTX » Topics » Second Quarter 2008 Accomplishments:
This excerpt taken from the TPTX 8-K filed Aug 8, 2008.
Second Quarter 2008 Accomplishments:
Announced that the company will hold an end of Phase II meeting on September 29, 2008 with the U.S. Food and Drug Administration to discuss the tezampanel
Phase III development plan for acute migraine.
Initiated a Phase I clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of tezampanel. The study will evaluate the effect of NGX426 on
hyperalgesia, an abnormally increased pain state, and allodynia, pain resulting from normally non-painful stimuli to the skin, induced by intradermal injections of capsaicin. This study, if successful, will allow the company to further benefit from
of the versatility of NGX426.
Presented data from the tezampanel Phase IIb clinical trial in acute migraine at the American Headache Societys Annual Scientific Meeting. The data showed
that in addition to meeting the primary endpoint of headache pain relief at two hours, tezampanel demonstrated improvement on important secondary endpoints including: sustained headache response, absence of nausea, absence of phonophobia and absence